UNIVERSITY OF MIAMI
The goal of this project is to carry out a set of definitive experiments on key novel concepts emanating from the original application currently under a non-cost extension and at the same time consolidating the team presently working in the project. Data suggest that vGPCR activation of Rac and ROS plays a major role in KSHV oncogenesis. In addition. we have now generated monoclonal antibodies to vGPCR that would allow us to interrogate clinical samples. AIM 1 is to study the role and mechanisms of vGPCR in Rac1 activation and ROS-production and their contribution to KSHV-induced oncogenesis. AIM2 is to use of a novel anti-vGPCR monoclonal antibody to study the association between vGPCR expression, KSHV lytic pathogenic-gene expression and molecular biomarkers of pathological phenotypes.